Cas 943540-75-8 JNJ 38877605 Receptor Tyrosine Kinase Inhibitor
Cas 943540-75-8 JNJ 38877605 Receptor Tyrosine Kinase Inhibitor
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:JNJ-38877605 |
Purity:98% min |
|
CAS NO:943540-75-8 |
Solubility:DMSO30 mg/mL (79.50 mM) |
|
Molecular Formula:C19H13F2N7 |
Package:Package according to customer requirements |
|
Molecular Weight:377.350 |
Storage:Store at -20℃ |
Quality control
Remarks
JNJ-38877605 is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. c-Met inhibitor JNJ-38877605 selectively inhibits c-Met (mesenchymal-epithelial transition), a receptor tyrosine kinase (RTK) involved in cancer cell survival and invasiveness, and tumor angiogenesis. c-Met is also known as hepatocyte growth factor receptor (HGFR).
Related Products
MGCD-265 analog; BMS777607; Tivantinib; AMG-208; AMG-458; NVP-BVU972; Golvatinib; SU11274; BMS-794833; PF-04217903; Crizotinib
References
[1].Perera T, et al. Presented at the 99th AACR Annual Meeting; 2008 Apr 12-16; San Diego (CA): Abst
[2].De Bacco F, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 2011 Apr, 103(8), 645-661.
[3].Torti D, et al. A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. Int J Cancer. 2012, 130(6), 1357-1366.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.